Quantcast

Latest Orphan drug Stories

2014-04-02 23:32:53

Cambridge Biomedical Inc. announces that their Chief Operating Officer, Dr. John Reddington, will be attending the 4th annual World Orphan Drug Congress in Washington D.C. April 23-25th, 2014 Boston, MA (PRWEB) April 02, 2014 Cambridge Biomedical’s experience with bioanalytical assay development, optimization, validation and diagnostic testing has proved instrumental in assisting biotechnology and pharmaceutical companies that are focusing on therapies for orphan and ultra-rare disease...

2014-03-31 20:22:33

DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5q5tcr/global_orphan) has announced the addition of the "Concise Analysis of the International Orphan Drug Market Outlook 2018" [http://www.researchandmarkets.com/research/5q5tcr/global_orphan ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global pharmaceutical industry has been experiencing a slow growth in recent...

2014-03-25 08:29:20

Frost & Sullivan: Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist MOUNTAIN VIEW, Calif., March 25, 2014 /PRNewswire/ -- The global orphan drugs market presents plenty of opportunities for new drug development - while there are only 172 approved orphan therapies, over 6,800 orphan diseases exist according to the United States National Institute of Health (NIH). Advancements in drug discovery capabilities coupled with regulatory and...

2014-03-22 12:21:28

DALLAS, March 22, 2014 /PRNewswire/ -- ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include...

2014-03-13 12:22:21

DUBLIN, Mar. 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fzkt7z/orphan_drugs ) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual...

2014-03-06 23:26:16

MarketReportsOnline.com adds "Europe Orphan Drug Market Outlook 2018" report to its research store. Dallas, Texas (PRWEB) March 06, 2014 Purchase the report for 20% discount. Offer valid until 31st March 2014. The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law,...

2014-02-27 23:03:20

Resolution Promotes Awareness of Rare Diseases Sacramento, CA (PRWEB) February 27, 2014 Today at the state Capitol, Assemblymember Kevin Mullin (D-South San Francisco), in partnership with the California Healthcare Institute (CHI), presented House Resolution 32 recognizing Feb. 28 as Rare Disease Day in California. CHI is a nonprofit, public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical...

2014-02-27 08:29:07

-- If isavuconazole is approved for invasive mucormycosis, QIDP status provides a five-year extension of market exclusivity -- NORTHBROOK, Ill., Feb. 27, 2014 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as...

2014-02-25 08:32:12

EASTBOURNE, England, February 25, 2014 /PRNewswire/ -- Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, today announced receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), Office of Orphan Products Development, for AIMSPRO(R) for the treatment of systemic sclerosis (scleroderma). "The granting of Daval's request for Orphan Drug Designation represents a...

2014-02-25 08:30:35

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.